These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25423927)

  • 21. Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease.
    Ginsberg C; Zelnick LR; Block GA; Chertow GM; Chonchol M; Hoofnagle A; Kestenbaum B; de Boer IH
    Nephrol Dial Transplant; 2020 Apr; 35(4):616-623. PubMed ID: 32160298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
    Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
    Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of phosphate binders in chronic kidney disease.
    Ketteler M; Biggar PH
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects.
    Frazão JM; Adragão T
    Nephron Clin Pract; 2012; 120(2):c108-19. PubMed ID: 22555359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?
    Locatelli F; Del Vecchio L
    J Nephrol; 2017 Dec; 30(6):755-765. PubMed ID: 28717990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current and potential treatment options for hyperphosphatemia.
    Carfagna F; Del Vecchio L; Pontoriero G; Locatelli F
    Expert Opin Drug Saf; 2018 Jun; 17(6):597-607. PubMed ID: 29783873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New Developments in CKD-MBD. Why is phosphate overload harmful?].
    Kuroo M
    Clin Calcium; 2014 Dec; 24(12):1785-92. PubMed ID: 25423923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment for CKD-MBD(Chronic Kidney Disease-Mineral and Bone Disorder)].
    Iwashita Y; Iwashita Y; Ito T; Shigematsu T
    Clin Calcium; 2016 Feb; 26(2):259-67. PubMed ID: 26813506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Iron-based Phosphate Binders for ESRD Patients].
    Cozzolino M; Mangano M; Magagnoli L; Di Lullo L; Galassi A; Brancaccio D; Bellasi A
    G Ital Nefrol; 2016; 33(4):. PubMed ID: 27545638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.
    Locatelli F; Del Vecchio L; Violo L; Pontoriero G
    Expert Opin Drug Saf; 2014 May; 13(5):551-61. PubMed ID: 24702470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
    Reiss AB; Miyawaki N; Moon J; Kasselman LJ; Voloshyna I; D'Avino R; De Leon J
    Atherosclerosis; 2018 Nov; 278():49-59. PubMed ID: 30253289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Chronic kidney disease--mineral and bone disorder: why and how to control phosphate].
    Pavlović D; Katicić D; Josipović J
    Acta Med Croatica; 2012 Oct; 66 Suppl 2():64-7. PubMed ID: 23513419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
    Bover J; Ureña-Torres P; Lloret MJ; Ruiz C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
    Expert Opin Pharmacother; 2016 Jul; 17(10):1363-73. PubMed ID: 27156578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Updates on the Mechanisms and the Care of Cardiovascular Calcification in Chronic Kidney Disease.
    Hénaut L; Chillon JM; Kamel S; Massy ZA
    Semin Nephrol; 2018 May; 38(3):233-250. PubMed ID: 29753400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New Developments in CKD-MBD. Development and progression of CKD-MBD in predialysis period -when and how?].
    Komaba H
    Clin Calcium; 2014 Dec; 24(12):1771-8. PubMed ID: 25423921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Kidney and bone update : the 5-year history and future of CKD-MBD. Progress of phosphate binders].
    Hanba Y; Masumoto A; Moribata M; Shigemathu T
    Clin Calcium; 2012 Jul; 22(7):1059-71. PubMed ID: 22750939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phosphate binders in moderate chronic kidney disease: where do we stand?
    Bellasi A; Cozzolino M; Adragao T; Di Iorio B; Russo D
    J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.
    Fukagawa M; Komaba H; Kakuta T
    Expert Opin Pharmacother; 2013 May; 14(7):863-71. PubMed ID: 23521343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials.
    Liu L; Wang Y; Chen H; Zhu X; Zhou L; Yang Y
    Ren Fail; 2014 Sep; 36(8):1244-52. PubMed ID: 25019348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.